Brian DeSchuytner's most recent trade in Mersana Therapeutics Inc was a trade of 281,250 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 281,250 | 281,250 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 62,500 | 62,500 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 14,583 | 129,863 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 14,583 | 43,750 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 0.58 per share. | 15 Jan 2025 | 8,470 | 121,393 (0%) | 0% | 0.6 | 4,913 | Common Stock |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 6,250 | 115,280 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 6,250 | 0 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 6,250 | 111,361 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 6,250 | 6,250 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 0.63 per share. | 14 Jan 2025 | 2,331 | 109,030 (0%) | 0% | 0.6 | 1,469 | Common Stock |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 10,000 | 108,824 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 10,000 | 20,000 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 0.66 per share. | 13 Jan 2025 | 3,713 | 105,111 (0%) | 0% | 0.7 | 2,451 | Common Stock |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 50,000 | 0 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 50,000 | 108,511 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 01 Oct 2024 | 8,089 | 100,422 (0%) | 0% | 2 | 16,178 | Common Stock |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 1.96 per share. | 01 Oct 2024 | 5,598 | 94,824 (0%) | 0% | 2.0 | 10,972 | Common Stock |
| Mersana Therapeutics Inc | DeSchuytner Brian | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2024 | 262,500 | 262,500 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2024 | 58,333 | 58,333 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 10,000 | 30,000 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | DeSchuytner Brian | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 10,000 | 47,380 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | DeSchuytner Brian | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 2.71 per share. | 13 Jan 2024 | 9,327 | 54,511 (0%) | 0% | 2.7 | 25,276 | Common Stock |
| Mersana Therapeutics Inc | DeSchuytner Brian | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 6,250 | 6,250 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | DeSchuytner Brian | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 6,250 | 12,500 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 6,250 | 55,630 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 6,250 | 59,880 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | DeSchuytner Brian | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 3,958 | 0 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, COO & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 3,958 | 63,838 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2023 | 180,000 | 180,000 | - | - | Stock option (right to buy) | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2023 | 40,000 | 40,000 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 6,250 | 12,500 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 6,250 | 18,750 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 6,250 | 33,954 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 6,250 | 27,704 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 13 Jan 2023 | 5,131 | 32,781 (0%) | 0% | 5.7 | 29,452 | Common Stock |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 3,958 | 37,912 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 3,958 | 3,958 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Brian DeSchuytner | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 112,500 | 112,500 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Brian DeSchuytner | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 25,000 | 25,000 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Brian DeSchuytner | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 10,208 | 17,573 (0%) | 0% | - | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 6,250 | 18,750 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Brian DeSchuytner | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 3,958 | 7,916 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Brian DeSchuytner | Sr. VP., FIN, Product Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 112,500 | 112,500 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Brian DeSchuytner | Sr. VP., FIN, Product Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 25,000 | 25,000 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Brian DeSchuytner | Sr. VP., FIN, Product Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 3,959 | 7,585 (0%) | 0% | - | Common Stock | |
| Mersana Therapeutics Inc | Brian DeSchuytner | Sr. VP., FIN, Product Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 3,959 | 11,874 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Brian DeSchuytner | Sr. VP., FIN, Product Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.09 per share. | 15 Jan 2021 | 1,162 | 6,423 (0%) | 0% | 21.1 | 24,507 | Common Stock |